Evidence map›Paper›PMID 26462281›Full record

ArticleBMJ open gastroenterology2015

Comparable efficacy with entecavir monotherapy and tenofovir-entecavir combination in chronic hepatitis B patients.

Sumbella Baqai, James Proudfoot, Ronghui Xu, Steve Kane, Margaret Clark, Robert Gish

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sumbella BaqaiDepartment of Internal Medicine , Eden Medical Center , Castro Valley, California , USA.
James ProudfootBiostatistics Unit , Clinical and Translational Research Institute, University of California, San Diego , San Diego, California , USA.
Ronghui XuDepartment of Mathematics , University of California, San Diego , San Diego, California , USA ; Department of Family and Preventive Medicine , University of California, San Diego , San Diego, California , USA.
Steve KaneInterventional Endoscopy Services , California Pacific Medical Center , San Francisco, California , USA.
Margaret ClarkIbrahim El-Hefni Liver Biorepository, Department of Transplantation , California Pacific Medical Center , San Francisco, California , USA.
Robert GishLiver Transplant Program , Stanford University Medical Center , Stanford, California , USA ; Hepatitis B Foundation , Doylestown, Pennsylvania , USA ; St. Joseph's Hospital and Medical Center, Phoenix, Arizona , USA ; University of Nevada , Las Vegas, Nevada , USA ; Robert G. Gish Consultants, LLC, San Diego, California, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe long-term goal for chronic hepatitis B patients is to maintain viral suppression in order to reduce disease progression risk. Because patients with previous treatment failure may have multiple viral resistance mutations, finding effective therapy is challenging. Because recent studies have shown that the combination of entecavir and tenofovir is effective in achieving virological response in many patients with prior treatment failure and multiple drug resistance mutations, we compared outcomes with this combination versus monotherapy.

methodsWith a retrospective chart review we compared results in 35 patients with previous treatment failure treated with the entecavir-tenofovir combination to results in patients treated with entecavir monotherapy.

resultsAlthough combination therapy resulted in significantly faster achievement of DNA negativity compared to entecavir monotherapy, the modest ten-week advantage is unlikely to be important for most patients since entecavir resistance develops extremely slowly. Significantly more patients on combination therapy experienced viral breakthroughs, most of which were attributed to non-adherence due to difficulties with the combination regimen.

conclusionsOur findings of reasonably comparable efficacy over time in the combination and monotherapy arms combined with the increased costs and compliance issues related to combination therapy weigh in favor of entecavir monotherapy in patients with previous treatment failure. However, because our study was a retrospective analysis of a small patient population, it will be important to confirm these findings with a randomised, controlled trial that compares these treatment approaches in treatment-experienced patients.

Indexed as

ADVERSE DRUG REACTIONSANTIVIRAL THERAPYHEPATITIS B

Identifiers

PMID26462281
PMCPMC4599168

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.